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Abstract
Background: The aim of the study was to develop a nude mouse xenograft model implanted with both benign
and malignant xenografts as the preliminary candidate screening tool for contrast agent development in lesion
malignancy indication.
Results: A malignant xenograft (either MCF-7 cell/matrigel™ or MDA-MB 231 cell/matrigel) and a benign xenograft
(culture medium/matrigel) with cleft and slit-like features of intracanaliculer fibroadenoma were implanted
subcutaneously into flanks of individual nu/nu nude mouse with >90 % successful inoculation rate. Both malignant
and benign xenografts with volume up to 4 cm3 and (size up to 2 cm) after 5th week were characterized in
vivo by sonogram (exhibiting endogenous morphological contrast features between benign and malignant
xenografts), dynamic contrast enhanced multi-detector computed tomography (presenting non-targeting
exogenous morphological and dynamic contrast features between benign and malignant xenografts), and
then were harvested for histological and immunohistochemistry (revealing example of targeting/molecular
contrast features, such as expression of cancer vascular markers of malignant xenografts). Malignant xenografts
appeared morphologically taller than wide (axis parallel to skin) with angular/ill-defined margin under
sonogram observations, revealed more evident rim enhancement, angular margin and washout pattern in the
time-density curve from dynamic contrast enhance multi-detector computed tomography images, and had
more visible cancer vascular markers (CD31 and VEGF) expression. With limited number of subjects (5–27 for
each group of a specific imaging contrast feature), those imaging contrast features of the xenograft model
had larger than 85 % sensitivity, specificity, accuracy, positive and negative prediction values in indicating
xenograft malignancy except for results from color Doppler detections.
Conclusions: The murine xenograft model might provide an earlier efficacy evaluation of new contrast agent
candidate for lesion malignancy interrogation with qualitative and quantitative indication before a human
study to reduce the risk and conserve the resources (time, finance and manpower).
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Background
An important part of breast cancer management is based
on the early screening of lesion malignancy and the effi-
cient evaluation of the lesion size/boundary for staging
analysis and therapy arrangement [1, 2]. Presently, the
invasive needle biopsy procedure is the gold standard in
malignancy screening, but it causes discomfort and has
the risk of facilitating metastasis due to detached tumor
cells caused by the procedure [3–5]. The development of
contrast agent enhanced imaging, such as sonogram (US),
dynamic contrast enhanced multi-detector computed
tomography (DCE-MDCT), magnetic resonance imaging
(MRI), and optical imaging etc., which targets the micro-
scopic molecular biomarker discrepancies (such as over
expression of epidermal growth factor receptor, EGFR or
Erb-1, by cancer cells) [6–9] or reveals the macroscopic
anatomical deviations (such as enhanced perfusion from
neovascular blood vessel in the cancer tissue) within
tumors, benign lesions and normal tissue [10–12], shows
promising potentials in both interrogating lesion malig-
nancy and delineating lesion boundaries non-invasively.
However, the requirements of adequate target quantities
(exceeding minimally topic accumulation concentra-
tion of contrast agent and minimally detectable lesion
dimension), relatively smaller market value (approximately
1/10 of therapeutic drugs), and equally strict regulations
compared to therapeutic agent innovation hamper the de-
velopment of new imaging agents [13, 14].
The therapeutic value of a leading drug candidate can
usually be identified through in vitro studies; however,
the feasibility of new contrast agents in specific clinical
applications always requires an in vivo model to provide
adequate target quantities for verification [13]. To de-
velop an agent for breast lesion malignancy screening,
the identification is more challenging; the specificity
generally cannot be accessed without human subject
studies, because the present animal models do not suffi-
ciently represent key features of clinically benign lesions
for screening with contrast agents [15, 16]. The carcino-
gen 7,12-dimethylbenz[a]anthracene (DMBA) was found
to induce both benign and malignant mammary lesions
in rats [17]. This DMBA-induced animal model is exten-
sively applied to investigate the mechanism of cancer or
the efficiency of preventative agents [18, 19]. However,
disadvantages of the model includes modest incidence
rate (~60 %), small tumor size (2–55 mm in diameter),
and the majority (>90 %) of the DMBA-induced benign
masses were glandular neoplasia, which account for
less than 10 % of human clinically benign lesions
[17]. Fibroadenoma (approximately 45 %) and fibrocystic
change (approximately 25 %) are the two major types of
clinically benign lesions requiring discrimination from
malignant masses [20, 21]. MMTV-c-erbB-2 and MMTV-
TGFα transgenic rats can also develop both malignant
and benign tumors with over 90 % of those breast abnor-
malities developing as benign fibroadenomas. The main
pitfall of this model is the low transgenic success rate
(7–14 %) even with the continued use of the pig follicle
stimulating hormone to assist transgene integration into
the rat gene sequence [22].
In this study, we are developing a murine xenograft
model bearing both malignant and benign xeografts
with similar dimension (up to 2 cm) and inoculation
position for eliminating the interferences from imaging
conditions (discrepancies between subjects due to con-
trast agent uptake and metabolism differences, or dis-
crepancies between lesions due to relative position
difference on subject causing different imaging acquisi-
tion conditions) as the preliminary candidate screening
tool for contrast agent development in malignancy
screening with endogenous morphological, non-targeting
exogenous or targeting contrasts. Having both type lesions
on the same subject renders possibility to demonstrate the
potential of contrast agent candidates in differentiating
lesion malignancy between benign and malignant tu-
mors from each imaging result of single subject with
both types of lesions, and reduces the required subject
number compared to mice with only malignant or benign
tumor implant alone in eliminating the interference from
discrepancies between subjects for qualitative and quanti-
tative indication of lesion malignancy. Clinically, there
were cases with coexistence of both malignant and benign
lesion in one subject [23, 24], and there was no evidence
suggesting that imaging features (benign or malignant)
will be modified by the co-presence of those two types of
lesion either in distance or nearby. The xenografts were
implanted subcutaneously into the flank region of nude
mice (Foxn1 gene disruption; athymic; nu/nu) for elimin-
ating interferences, such as the accumulation of agents in
organs (liver, kidneys, bladder, intestine) responsible for
their clearance (stronger contrast enhancement of organs
hindering signal from xenograft and resulting in specificity
reduction from hindered contrast enhanced indicating
malignancy from xenografts’ signal in abdominal area,
such as orthotopical breast xenograft), and the unwanted
signal interferences from animal hair absorption or scat-
tering [25, 26]. The MDA-MB 231 or MCF-7 cell/matrigel
mixture was implanted and allowed to develop to repre-
sent the malignant cancer tissue, and the cell culture
medium/matrigel mixture was implanted and allowed to
stabilize with the surrounding tissue to mimic the solid
mass of a benign tumor. The application of matrigel
matrix in malignant xenografts has been proven to signifi-
cantly enhance the grating rate without the requirement
of immunosuppressive conditionings (irradiation or medi-
cation) before inoculation, while allowing the xenograft
to exhibit the histomorphology and molecular markers
of cancers [27, 28]. For the benign implant, we created
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a porous matrigel plug with infiltrated fibrotic cells, in-
stead of mixing benign human breast cell lines (such as
MCF-10 or human breast tissue/primary culture) with
matrigel matrix, which formed neovasculation (the
source of non-specific contrast of conventional contrast
enhanced US, DCE-MDCT and MRI that could result
in misinterpretation of malignancy of such cell/matrigel
benign xenograft) in mice and may evolve into a malig-
nant tumor [27–30]. The two xenografts were then
characterized by in vivo imaging inspections (US, CT)
to verify the presence of those endogenous morpho-
logical and non-targeting exogenous contrasts. Immu-
nohistological analysis of CD31 and VEGF (indications
of neovascular development and facilitators for uncon-
trolled growth, invasion and metastasis of breast cancer
[31–33]) in xenograft sections indicated the presence of
the endogenous targeting contrasts.
Methods
Murine xenograft model for lesion malignancy screening
Nu/nu nude mice (aged 7–9 weeks, 31.3 ± 3.7 g), pur-
chased from BioLASCO Taiwan Co., LTD. (Yilan, Taiwan),
were maintained and studied using procedures approved
by the Institution Animal Care and Use Committee of
National Chung Hsing University (IACUC Approval
No. 100–71). Two to three mice were housed to each cage
in an individually ventilated, temperature (23 ± 2 °C) and
humidity (50–55 %) controlled facilities, on 12 h light,
12 h dark cycle, and had free access to sterilized laboratory
chow and water.
The human breast adenocarcinoma cell line, MCF-7
and MDA-MB 231, were obtained from the National
Health Research Institute Cell Bank (Hsinchu, Taiwan)
and cultured as recommended by the American Type
Culture Collection (Manassas, Virginia, USA) with cul-
ture reagents obtained from Quantum Biotechnology
(distributor of Life Technologies, Inc. and Invitrogen,
Taichung, Taiwan) unless otherwise indicated. The cell
culture medium was Dulbecco Modified Eagle Medium
(DMEM) with 10 % fetal bovine serine (FBS).
Approximately 0.5 ml mixtures (volume ratio = 1:1) of
matrigel matrix (Bertec Enterprise Co. Ltd., distributor of
BD Bioscience, Taichung, Taiwan) and culture medium
(DMEM with 10 % FBS) with or without the suspension
of 1 × 107 cancer cells were injected subcutaneously into
both dorsal flanks (the same level above the dorsal-ventral
adjunction) of the mice to grow xenografts. The mixtures
without cells were agitated vigorously to incorporate air
bubbles before implantation. The general performance
and survival of the mice were monitored twice weekly,
and the dimensions of the xenografts (longitudinal length
and transverse width) were measured using an electronic
digital caliper (Long Jer Precise Industry Co. Ltd.,
Taichung, Taiwan), and the measurements were applied in
calculating the xenograft volume (π/6 × width2 × length).
The xenografts were allowed to develop for specific
durations of time as described below before further
characterization with in vivo imaging inspections and
histological analysis.
Sonogram
High resolution sonograms of the xenografts were acquired
using a GE Logiq 700 Expert (GE Healthcare, USA) with a
9–12 MHz linear transducer. Before the examination, the
mice received an anesthetic agent, Zoletil (zolazepam
hypochloride : tiletamine hypochloride = 1 : 1, Virbac Ltd.,
Milperra, New South Wales, Australia), by intramuscular
injection at the dosage of 20–30 mg/kg. The localization
and anatomical boundary of the xenografts were investi-
gated first by the gray scale mode detection. The color
Doppler measurements were followed to monitor the
blood flow in the xenograft.
DCE-MDCT scan
DCE-MDCT images were acquired using a Philips BR64
(Andover, MA, USA). Before and during the examination
periods, anesthesia of the mice was initiated and main-
tained using the inhalation of isoflurane (Halocarbon,
River Edge, NJ, USA) in oxygen (1 % to 2.5 % isoflurane)
through a customized mask made specifically for mice.
Theclinically approved and well adapted contrast agent,
iobitridol (Xenetix, Guerbert, France),was adminis-
trated intravenously as a bolus through the tail vein at
the clinical dosage of 1 mg/g [34]. Generally, a volume
of 100 μl solution at the concentration of 300 mg iod-
ine/ml was injected for a 30 g subject. The images were
scanned with the following settings: 0.5 s rotation time,
80 kV, 80 mAs, 0.6 mm beam collimation, and 1 mm
slice thickness at different time points after contrast
agent administration and were transferred to a PACS
workstation (Centricity, GE Medical Systems, Milwaukee,
WI, USA) for quantification evaluation. For signal quanti-
fication, signal intensity (SI) of xenografts were measured
(Hounsfield), and the contrast ratio were calculated as
SIt/SIi, where SIt was the measured intensity at time t
and SIi was the measured initial intensity.
Histology analysis and blood vessel density profile of the
xenografts
All of the reagents used in the procedure were purchased
from BD Bioscience. The xenografts were harvested after
sacrificing the mice, fixed in 10 % buffered formalin,
paraffin-embedded, and sectioned. Major organs, such as
the liver, lungs, pancreas, kidneys, spleen, heart, intestine
and colon were removed and formalin-fixed for further
inspection for metastases. The xenograft specimens for
histological analysis were processed with conventional
hematoxylin and eosin (H&E) staining for the visualization
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of general tissue morphology and mitotic figures under
microscopic inspection. Percentage of neo-vascular blood
vessel distributed area in stained xenografts were inspected
using a microscope (AF 6000, Leica, Wetzlar, Germany)
equipped with a mechanical stage, and linked to a
digital color camera (DFC 300, Leica, Wetzlar, Germany)
transferring the microscopic images to computer monitor.
The presence of neo-vascular blood vessel in xenografts
was identified at a magnification of 400×, and the area
(same pattern of cell distribution) with neo-vascular
blood vessel and boundary of xenografts were marked
manually at a magnification of 100× (covering more
than 60 % cross-section area of all xenograft images).
Percentage of neo-vascular blood vessel distributed
area in each xenograft image was calculated by Image
J software (1.48v, NIH, USA) with the equation:
Areablood vessel area / Areaxenograft × 100 %.
Immunohistochemistry of the xenografts
The immunohistochemistry (IHC) of specimens were
stained either with rat-anti-mouse CD31 (1:100 dilution,
NCL-CD31-1A10, Novocastra™ Lyophilized Mouse
Monoclonal Antibody, Leica Biosystems Newcastle Ltd,
UK) or a rabbit polyclonal VEGF antibody (Biorbyt
Limited, Cambridge, Cambridgeshire, UK). After deparaf-
finization and rehydration, formalin-fixed paraffin sections
were incubated in 3 % H2O2 in distilled water for 30 min
at room temperature followed by an antigen retrieval
step carried out by boiling the slides in 0.01 M of citrate
buffer for 20 min. The sections were washed in 50 mM
Tris–HCl, 0.05 % Tween, pH 7.6 for 2 min. To block non-
specific binding, all of the sections were treated with 5 %
skim milk for 30 min at room temperature. The slides
were then incubated with a primary antibody (1:100 dilu-
tion for CD31; 1:400 dilution for VEGF) for 2 h at 4 °C.
The reaction was stopped by rinsing the section with
0.01 M phosphate-buffered saline (PBS). The slides were
then incubated with a biotinylated anti-mouse/rabbit IgG
serum (secondary antibody) as a linking reagent, followed
by treatment with a peroxidase-labeled streptavidin-biotin
complex and diaminobezidine substrate to visualize the
positive cells. Finally, the sections were counterstained
with hematoxylin prior to being mounted for light micros-
copy examination.
Results
In the study, 100 % (17/17) of the MDA-MD 231 xe-
nografts, 90.9 % (20/22) of the MCF-7 xenografts and
92.3 % (36/39) of the benign xenografts successfully
developed in vivo for image acquisitions and were
harvested for histology/IHC analysis. Volume of the
benign xenografts reduced gradually (about 2.3 % per
week); volume of the MDA-MB 231xenografts had
more modest increase (less than 7 % per week) in the
initial 6–8 weeks post inoculation and more dramatic
growth (about 20 % per week) later; volume of the MCF-7
implants had much mild increase (less than 0.37 %) (Fig. 1)
compared to MDA-MB 231 xenografts. No evident metas-
tasis related to the xenograft inoculations was observed
with only one subject (with MCF-7 and matrigel xeno-
grafts) showing signs of a spleen anomaly at 26 weeks
after receiving both benign and malignant implants.
Histological and immunohistochemical findings of the
xenografts
The bright field microscopic images of the paraffin-
embedded, sectioned tissue slices with hematoxylin &
eosin staining indicated that MCF-7 tumor masses grew
from initial enlarged cysts into solid masses with central
necrosis after 5 weeks post implantation (Fig. 2). There
were newly-formed blood vessels on the surface of both
fully developed malignant xenografts (after 5 weeks
post inoculation) identified in situ (Figs. 3a and 4a) and
from the harvested tissues (Figs. 3b and 4b), and inside
Fig. 1 Size of malignant and benign xenografts at time points post implantation. There were 20 MDF-7, 17 MDA-MD 231 and 36 benign
xenografts. The xenograft volumes are calculated by dimensions measured with an electronic digital caliper using the following
equation: volume = π/6 × width2 × length
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the tumor masses indicated by histological H&E stain-
ing (Figs. 5a and 6a) or immunohistochemical CD31
staining (Figs. 5b and 6b). The immunohistochemical
VEGF staining showed elevated expression of the cancer
pathology-related molecular marker associated with both
cell lines [35–38] around region of neovascular vessels
(Figs. 5c and 6c).
The benign masses appeared as pink-colored blocks
under histological H&E staining, and were infiltrated and
encapsulated by fibrotic cells exhibiting fibroadenoma-like
Fig. 2 Morphology of MCF-7 xenografts at time points post implantation. The paraffin-embedded, sectioned tissue slices with hematoxylin &
eosin staining to visualize morphology were examined by bright field microscopy. a Tumor masses were grown as enlarged cysts with numerous
adenoid rosette structures with tumor cell groups distributed inside the matrigel wall at 72 h post implantation. b, c The tumor cells gradually
proliferated and aggregated near the exterior edge of the matrigel wall at 1–3 weeks post implantation. d The xenografts developed as solid
masses with central necrosis after 5 weeks post implantation
Fig. 3 Morphology of fully developed (5-week) MDA-MB 231 xenograft with necrotic core and neovascular blood vessel on the surface or within
the mass. There were newly-formed blood vessels on the surface of the developed xenografts identified in situ (a) and from the harvested tissue
(b) and inside the tumor mass with histological H&E staining indicated by black arrow heads (d), which was magnified from the green lines
marked region in (c). The cells with mitotic figures are indicated by black arrows in (d)
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ductal or slit shaped openings inside the xenografts (Fig. 7c
and d) [39, 40]. There were no noticeable newly-formed
blood vessels on the surface of either the xenografts in
situ (Fig. 7a) or from the harvested tissue (Fig. 7b), or
inside the developed mass as indicated by histological
H&E staining (Fig. 8a) or immunohistochemical CD31
staining (Fig. 8b). The immunohistochemical VEGF
staining showed no evidence of elevated expression in-
side the xenografts (Fig. 8c).
Morphology and neovascular blood flow of xenografts
under sonogram
Randomly chosen 54 developed xenografts (10 MDA-MB
231, 17 MCF-7 and 27 benign xenogrsfts) were inspected
by sonogram. Both malignant xenografts (MDA-MB 231
and MCF-7) grew relatively taller than wide (axis parallel
to skin) in orientation with width(axis parallel to skin)/
height values from scans with longitudinal orientation of
transducer at 1.27 ± 0.25, 1.34 ± 0.31 of MDA-MB 231 and
Fig. 4 Morphology of fully developed (5-week) MCF-7 xenograft with necrotic core and neovascular blood vessel on the surface or within the mass.
There were newly-formed blood vessels on the surface of the developed xenografts identified in situ (a) and from the harvested tissue (b) and inside
the tumor mass with histological H&E staining indicated by arrow heads (d), which was magnified from the green lines marked region in (c)
Fig. 5 Immunohistochemistry of MDA-MB 231 xenograft. The newly-formed blood vessels appeared inside the tumor mass with histological H&E
staining (a) and CD31 staining (b) indicated by black arrow heads. The VEGF staining exhibited an elevated expression of the cancer pathology-related
molecular marker around the region of neovascular vessels indicated by black arrow heads (c)
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MCF-7 xenografts respectively, compared to 2.94 ± 0.29 of
benign xenografts. They also had angular/ill-defined mar-
gins (penetrating into adjacent derma layer structures)
(Fig. 9a). The detection rate of increased blood flow in the
tumor xenografts from color Doppler imaging was 17.6 %
(3/17) for MCF-7 xenografts (Fig. 9c) and 10 % (1/10) for
MDA-MB 231 xenografts.
The benign masses appeared to have a flat disk-like
shape (Fig. 9b). The color Doppler imaging did not show
signs of increased blood flow around in any of the be-
nign xenografts (Fig. 9d).
Morphology and time-density signal profile of xenografts
under DCE-MDCT
Randomly chosen 46 developed xenografts (11MDA-MB
231, 12 MCF-7 and 23 benign implants) involved in the
DCE-MDCT scan. The average whole body signals (in
the unit of Hounsfield) reached peak values in minutes
Fig. 6 Immunohistochemistry of MCF-7 xenograft. The newly-formed blood vessels appeared inside the tumor mass indicated with H&E staining
(a) and CD31 staining (b) indicated by black arrow heads. The VEGF staining exhibited an elevated expression of the cancer pathology-related
molecular marker around the region of neovascular vessels indicated by black arrow heads (c)
Fig. 7 Morphology of the developed (5-week) benign xenograft. There were no noticeable newly-formed blood vessels on the surface of either
the xenograft in situ (a) or in the harvested tissue (b) or inside the developed mass with histological H&E staining (c). The benign masses appeared as
pink-colored blocks and were infiltrated by fibrotic cells exhibiting cleft- or slit-like openings inside the xenografts (c, d)
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after agent administration and plummeted dramatically,
maintaining 50 % of the contrast enhancement for less
than 15 min in all of the trials. However, the iobitridol
contrasted images indicated that the malignant implants
had a more significant contrast enhancement than the
benign implants when reaching maximal enhancement
(Fig. 10a). MDA-MB 231 xenografts had 620 % maximal
contrast enhancement compared to the initial mean
value (without contrast medium) approximately 30 min
after contrast agent administration and washout-like
decline to lose 33.9 % contrast enhancement in the
following 60 min with interpolated half-life for 67 min
after reaching the peak value (30th minute) or at 97th
minute; MCF-7 xenografts had 467 % maximal contrast
enhancement approximately 60 min after contrast agent
administration and washout-like decline to lose 37 %
contrast enhancement in the following 60 min with in-
terpolated half-life for 71 min after reaching the peak
Fig. 8 Immunohistochemistry of benign xenograft. There were no noticeable newly-formed blood vessels inside the developed mass with histological
H&E staining (a) or immunohistochemical CD31 staining (b). The immunohistochemical VEGF staining exhibited no evidence of elevated expression
inside the xenografts (c)
Fig. 9 Sonograms and Doppler imaging of developed xenografts in vivo. The longitudinal cross-section images (a, c) were acquired from malignant
xenografts. The transverse cross-section images (b, d) were acquired from the benign xenografts. The color Doppler imaging (c, d) quantifies the vascular
flow velocity around the xenograft and surrounding region by pseudo colors. The green cursers indicate corresponding xenograft lengths, 0.76 cm in (a)
and 1.18 cm in (b). The morphology of malignant xenograft (MCF-7 xenograft) was demonstrated in (a) with angular/ill-defined margin (orange arrows)
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value (60th minute) and lasting to 131st minute (Fig. 11c).
The benign implants showed a relatively milder maximal
contrast enhancement (205 %) in a more extended
period (exhibited as a plateau lasting from 60th to 180th
minutes). Its interpolated contrast enhancement half-life
for 297 min after reaching the peak value (90th minute)
and lasting to 387th minute.
The xenograft type dependent features (contrast en-
hancement maximal values and half-life durations) cor-
relates positively with the xenograft type dependent
percentage of neo-vascular blood vessel distributed areas
(Fig. 11a and b). MDA-MB 231 xenografts, which had
the highest percentage of neo-vascular blood vessel dis-
tributed areas at a magnification of 100× (covering more
than 60 % cross-section area of all xenograft images), re-
sulted in the most maximal contrast enhancement value
and the shortest contrast enhancement half-life duration
(Fig. 11c). Benign xenografts, which had no detectable
newly-formed blood vessels on the surface of (Fig. 7a and
7b) or within the developed masses (Fig. 11a and b),
caused the least maximal contrast enhancement and the
longest contrast enhancement half-life duration (Fig. 11c).
In examining the morphological features of the xenograft
images under DCE-MDCT, the most visible features that
could be used to indicate the malignancy of xenografts
were the angular/ill-defined margin and rim enhancement.
All of the malignant xenografts showed rim enhancement
in the initial contrast enhanced period before reaching a
peak value with more homogeneous enhancement for the
whole xenograft (Fig. 10a). The average enhancement
value (Hounsfield) of the rim increased more than 40 %
compared to the average value of the central region. Only
8.7 % (2/23) of the benign xenografts showed signs of rim
enhancement, while none of them had more than a 25 %
increase compared to the average value of the central re-
gion. During the same initial contrast enhanced period
showing rim enhancement, most of the malignant xeno-
grafts (11/11 or 100 % of MDA-MB 231 xenografts; 11/12
or 91.7 % of MCF-7 xenografts) had angular/ill-defined
margin, while none of the benign xenografts showed sign
of angular/ill-defined margin.
Discussions
The preliminary results demonstrate that the xenograft
model at 5th week (with fully developed anatomical
features of lesions and similar sizes between xenografts)
exhibits clinical malignancy indicating features of xe-
nografts by endogenous contrasts (taller than wide in
orientation, angular/ill-defined margin), non-targeting
contrasts (neovascular vessel enhanced perfusion related
rim enhancement and time-density patterns), and mo-
lecular targeting contrast (cancer marker expression).
The xenograft-type occurrence of those contrast features
are summarized in Table 1. Corresponding accuracy, sen-
sitivity, specificity, positive predictive value and negative
predictive value of those contrast features are shown in
Table 2.
With limited number of subjects (5–27 for each con-
trast feature analysis compared to clinical studies with
much larger than 100 [15, 16]), each occurrence of false
positive (indicating malignancy for benign xenograft) or
false negative (not indicating malignancy for malignant
xenograft) greatly reduce accuracy, sensitivity, specificity,
positive predictive value and negative predictive value by
1.8–5 %. However, most of the contrast features achieved
exceeding 85 % accuracy, sensitivity, specificity, positive
predictive value and negative predictive value except
for the contrast from neovascular blood flow detected
by color Doppler US. Those contrast features of the
xenograft model with high (exceeding 85 %) accuracy,
sensitivity, specificity, positive predictive value and nega-
tive predictive value, surpassing the evaluation efficiency
from 3 conventional imaging modalities (mammogram
had 70.2 % accuracy, 67.8 % sensitivity, 75 % specificity
and 85.7 % positive predictive value; US had 67.8 % accur-
acy, 83 % sensitivity, 34 % specificity and 73.5 % positive
predictive value; MRI had 72.9 % accuracy, 94.4 % sensi-
tivity, 26 % specificity and 73.6 % positive predictive value)
for breast lesion screening [15]. It verifies that the xeno-
graft model can be applied as the preliminary candidate
screening tool for contrast agent development in lesion
Fig. 10 DCE-MDCT of xenografts. The acquisition at time points post
iobitridol injection is indicated below each image with the positions
of the MDA-MB 231 xenografts indicated by red arrows and the benign
xenografts indicated by white arrow heads. a The rim enhancement of
malignant xenografts (MDA-MB 231) was demonstrated after iobitridol
administration. b The green lines marked areas in (a) are magnified
to demonstrate the angular/ill-defined margin (orange arrows) of
malignant xenografts (MDA-MB 231)
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malignancy indication with reduced number of sub-
jects, because bearing both malignant and benign xe-
nografts on the same subject with similar size and
inoculation position can eliminate the interferences
from imaging conditions (discrepancies between subjects
due to contrast agent uptake and metabolism differences,
or discrepancies between xenografts due to relative
position difference on subject causing different imaging
acquisition conditions).
The neovascularity related blood flow detected by
color Doppler US was the only inconclusive contrast fea-
ture of the xenograft model in indicating the malignancy
of malignant xenografts with low occurrence frequency
of true positive events (17.6 %, 3/17, for MCF-7 xeno-
grafts and 10 %, 1/10, for MDA-MB 231 xenografts) and
correspondingly poor accuracy (57.4 %), sensitivity
(14.8 %) and negative predictive value (54 %). One of the
potential reason is that the application of probe pressure
caused deformation of blood vessel, obstruction of
the vascular blood flow and therefore the malignant
xenografts appeared to resemble an avascular xenograft/
lesion [41–43]. Another explanation could be the limited
capability of Doppler-based imaging to detect low velocity
(<1 cm/s) blood flow from small blood vessels of xenograft
neovascularity [44].
For conventional DCE-MDCT for lesion malignancy
screening, angular/ill-defined margin (99–100 %) and
rim enhancement (100 %) are the most predictive CT
clinical features of breast lesion malignancy with high
accuracy, while a washout pattern on postcontrast im-
ages has high sensitivity (91 %) on positive malignant
lesions but low specificity (48 %) with high false positive
occurrence rate (42 %) [45, 46]. Clinically, washout pat-
tern in conventional DCE-MDCT have abruptly decline
happened in 10 min after contrast medium injection
[47], however the half-life of washout-like pattern from
Fig. 11 Xenograft type dependent percentage of neo-vascular blood vessel distributed area and time-density profiles under DCE-MDCT. a Neo-vascular
distributed areas in H&E stained xenografts are marked and quantified at a magnification of 100×. The lesion type dependent percentages
of neo-vascular blood vessel distributed area indicated by values in the red parentheses as mean ± standard deviation %. There were 20 MDF-7, 17
MDA-MD 231 and 36 benign xenografts. b The green lines marked areas in (a) are magnified to demonstrate the xenograft type dependent neo-vascular
blood vessel distribution at a magnification of 400×. c Time-density profiles of xenografts detected by iobitridol contrasted dynamic CT scan
Yen et al. Journal of Biomedical Science  (2016) 23:46 Page 10 of 13
malignant xenografts of the xenograft model detected by
DCE-MDCT approached 70 min. The potential reason
for the prolonged washout-like pattern is that the sub-
cutaneous xenografts were inoculated in the artificial
flank area for the advantage of reducing interference from
major organs (which are responsible for contrast agent ex-
cretion and accumulate with them, or have higher blood
vessel densities to cause higher contrast enhancement and
hinder the signal from xenografts) and the corresponding
disadvantage with less interaction with central circulation
(less purfusion) as the actual malignant lesion [48].
From the preliminary detection results of the two avail-
able clinical medical imaging modalities, US appropriately
indicated endogenous morphological contrast features
between benign and malignant xenografts of the animal
model associated with density/echogenicity deviation
of lesion tissue, while DCE-MDCT adequately presented
non-targeting exogenous morphological and dynamic
contrast features between benign and malignant xeno-
grafts related to regionally time-dependent or neovascular
density dependent contrast agent distribution.
The developing xenograft model for contrast agent
screening had limitations. Both types of xenografts were
not orthotopic lesions, which might not fully recapitu-
late the characteristics of actual lesions in human breast
due to lack of micro-cellular environment mimicking
human breast gland with stromal component of tumor
origin, lower level exposure of systematic hormones and
growth factors from mice than human [49, 50]. Results
obtained from the models cannot precisely predict the
Table 2 Reliability of contrast features from the model for malignancy prediction
Contrast features (Method) Accuracy Sensitivity Specificity PPV NPV
Molecular targeting contrast CD31 (IHC) 100 % 100 % 100 % 100 % 100 %
VEGF (IHC) 100 % 100 % 100 % 100 % 100 %
Non-targeting contrast Rim enhancement (DCE-MDCT) 93.5 % 95.7 % 91.3 % 91.7 % 95.5 %
Time-density curve 91.3 % 86.9 % 100 % 100 % 88.5 %
Washout T1/2 < 100 min (DCE-MDCT)
Endogenous contrast Angular/ill-defined margin (grey scale US) 92.6 % 85.2 % 100 % 100 % 100 %
Angular/ill-defined margin (DCE-MDCT) 93.5 % 87 % 95.7 % 95.2 % 87 %
Orientation width/height > 2.2 (grey scale US) 100 % 100 % 100 % 100 % 100 %
Neovascular flow (color Doppler US) 57.4 % 14.8 % 100 % 100 % 54 %
TPMDA = number of true positive (indicating malignancy) of MDA-MB 231 xenografts; TPMCF = number of true positive (indicating malignancy) of MCF-7 xenografts;
TN = number of true negative (not indicating malignancy) of benign xenografts; FP = number of false positive (indicating malignancy) of benign xenografts; FNMDA = number
of false negative (not indicating malignancy) of MDA-MB 231 xenografts; FNMCF = number of false negative (not indicating malignancy) of MCF-7 xenografts;
accuracy = (TPMDA + TPMCF + TN)/(TPMDA + TPMCF + FNMDA + FNMCF + TN + FP) × 100 %; sensitivity = (TPMDA + TPMCF)/(TPMDA + TPMCF + FNMDA + FNMCF); specificity =
TN/(TN + FP); PPV (positive predictive value) = (TPMDA + TPMCF)/(TPMDA + TPMCF + FP); NPV (negative predictive value) = (TN)/(FNMDA + FNMCF + TN); washout T1/2 = half-life
of washout-like contrast pattern
Table 1 Occurrence of contrast features from the model for malignancy prediction
Contrast features (Method) Xenograft types Occurrence (frequency %)
Malignant Benign
MDA-MB 231 MCF-7
Molecular targeting contrast CD31 (IHC) 5/5 (100 %) 6/6 (100 %) 0/11 (0 %)
VEGF (IHC) 5/5 (100 %) 6/6 (100 %) 0/11 (0 %)
Non-targeting contrast Rim enhancement (DCE-MDCT) 11/11 (100 %) 11/12 (100 %) 2/23 (8.7 %)
Time-density curve
Washout T1/2 < 100 min (DCE-MDCT) 10/11 (90.9 %) 10/12 (83.3 %) 0/23 (0 %)
Endogenous contrast Angular/ill-defined margin (grey scale US) 9/10 (90 %) 14/17 (82.4 %) 0/27 (0 %)
Angular/ill-defined margin (DCE-MDCT) 10/11 (90.9 %) 9/12 (75 %) 1/23 (4.3 %)
Orientation
width/height > 2.2 (grey scale US) 10/10 (100 %) 17/17 (100 %) 0/27 (0 %)
Neovascular flow (color Doppler US) 1/10 (10 %) 3/17 (17.6 %) 0/27 (0 %)
Occurrence = occurred number of specific type xenograft/total number of specific type xenograft; frequency % = occurred number of specific type xenograft/total
number of specific type xenograft × 100 %
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clinical sensitivity, specificity, accuracy, positive and
negative prediction values of the screened contrast
agent candidate in actual medical use. However, those
xenografts had mimicking 3 days structure of benign
and malignant lesions, endogenous targeting features
or exogenous non-targeting features for potential con-
trast agents, and allowed quick indication of contrast
agent potential in malignancy assessment by eliminating
discrepancies between subjects and revealing contrast
agent potential qualitatively and quantitatively in each
imaging acquisition.
Conclusions
In conclusion, the xenograft model exhibiting clinical
endogenous, non-targeting exogenous, and molecular
targeting contrasts, has the potential to be applied as the
low cost preliminary screening tool for testing contrast
agents candidates of conventional imaging or molecular
imaging (except for color Doppler contrast agents) with
the advantage to inoculate both benign and malignant
xenografts on the same subject and eliminate the inter-
ference from difference between individual subjects, and
to reduce the required subject numbers. This model
might provide an earlier efficacy evaluation of new con-
trast agent candidate for lesion malignancy interrogation
before a human study to reduce the risk and conserve
the resources (time, finance and manpower).
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